MicroRNA-27a Induces Mesangial Cell Injury by Targeting of PPARγ, and its in Vivo Knockdown Prevents Progression of Diabetic Nephropathy

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Wu, Lina ^a   Wang, Qingzhu ^a   Guo, Feng ^a   Ma, Xiaojun ^a   Ji, Hongfei ^a   Liu, Fei ^a   Zhao, Yanyan ^a   Qin, Guijun ^a  

^a ZHENGZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; MICRORNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ANIMAL; CELL PROLIFERATION; COMPLICATION; DIABETIC NEPHROPATHY; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; MESANGIUM CELL; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT;

ANIMALS; CELL PROLIFERATION; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; GLUCOSE; MESANGIAL CELLS; MICRORNAS; PPAR GAMMA; RATS;

EID: 84968756818     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep26072     Document Type: Article

References (39)

1. Brosius, F. C., Khoury, C. C., Buller, C. L. & Chen S. Abnormalities in signaling pathways in diabetic nephropathy. Expert. Rev. Endocrinol. Metab. 5, 51-64 (2010).
2. Mason, R. M. & Wahab, N. A. Extracellular matrix metabolism in diabetic nephropathy. J. Am. Soc. Nephrol. 14, 1358-1373 (2003).
3. Tsuchida, K., Zhu, Y., Siva, S., Dunn, S. R. & Sharma, K. Role of Smad4 on TGF-beta-induced extracellular matrix stimulation in mesangial cells. Kidney Int. 63, 2000-2009 (2003).
4. Bartel, D. P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281-297 (2004).
5. Ambros, V. The functions of animal microRNAs. Nature 431, 350-355 (2004).
6. Farh, K. K. et al. The widespread impact of mammalian MicroRNAs on mRNA repression and evolution. Science 310, 1817-1821 (2005).
7. Esquela-Kerscher, A. & Slack, F. J. Oncomirs - microRNAs with a role in cancer. Nat. Rev. Cancer 6, 259-269 (2006).
8. Lagos-Quintana, M. et al. Identification of novel genes coding for small expressed RNAs. Science 294, 853-858 (2004).
9. Xiao, C. & Rajewsky, K. MicroRNA control in the immune system: basic principles. Cell 136, 26-36 (2009).
10. Chhabra, R., Dubey, R. & Saini, N. Cooperative and individualistic functions of the microRNAs in the miR-23a-27a-24-2 cluster and its implication in human diseases. Mol. Cancer 9, 232 (2010).
11. Nielsen, L. B. et al. Circulating levels of microRNA from children with newly diagnosed type 1 diabetes and healthy controls: evidence that miR-25 associates to residual beta-cell function and glycaemic control during disease progression. Exp. Diabetes Res. 2012, 896362 (2012).
12. Karolina, D. S. et al. Circulating miRNA profiles in patients with metabolic syndrome. J. Clin. Endocrinol. Metab. 97, E2271-6 (2012).
13. Herrera, B. M. et al. Global microRNA expression profiles in insulin target tissues in a spontaneous rat model of type 2 diabetes. Diabetologia 53, 1099-1109 (2010).
14. Kim, S. Y. et al. miR-27a is a negative regulator of adipocyte differentiation via suppressing PPARγ expression. Biochem. Biophys. Res. Commun. 392, 323-328 (2010).
15. Yang, J. et al. Role of PPARγ in renoprotection in Type 2 diabetes: molecular mechanisms and therapeutic potential. Clin. Sci. 116, 17-26 (2009).
16. Yang, J., Zhou, Y. & Guan, Y. PPARγ as a therapeutic target in diabetic nephropathy and other renal diseases. Curr. Opin. Nephrol. Hypertens. 21, 97-105 (2012).
17. Kang, B. Y. et al. Hypoxia mediates mutual repression between microRNA-27a and PPARγ in the pulmonary vasculature. PLoS One 8, e79503 (2013).
18. Okada, T. et al. Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms. Diabetes 55, 1666-1677 (2006).
19. Asano, T. et al. Peroxisome proliferator-activated receptorγ 1(PPARγ1) expresses in rat mesangial cells and PPARγ agonists modulate its differentiation. Biochim. Biophys. Acta 1497, 148-154 (2000).
20. Zheng, F. et al. Upregulation of type I collagen by TGF-beta in mesangial cells is blocked by PPARγ activation. Am. J. Physiol. Renal Physiol. 282, F639-F648 (2002).
21. Kolavennu, V., Zeng, L., Peng, H., Wang, Y. & Danesh, F. R. Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control. Diabetes 57, 714-723 (2008).
22. Xu, Z. G. et al. Relationship between 12/15-lipoxygenase and COX-2 in mesangial cells: potential role in diabetic nephropathy. Kidney Int. 69, 512-519 (2006).
23. -ΔΔCT method. Methods 26, 402-408 (2001).
24. Yang, F., Chung, A. C., Huang, X. R. & Lan, H. Y. Angiotensin II induces connective tissue growth factor and collagen I expression via transforming growth factor-beta-dependent and -independent Smad pathways: the role of Smad3. Hypertension 54, 877-884 (2009).
25. Zhou, L. et al. Mechanism and function of decreased FOXO1 in renal cell carcinoma. J. Surg. Oncol. 105, 841-847 (2012).
26. Wu, L., Zhang, Y., Ma, X., Zhang, N. & Qin, G. The effect of Resveratrol on FoxO1 expression in kidneys of diabetic nephropathy rats. Mol. Biol. Rep. 39, 9085-9093 (2012).
27. Miceli, I. et al. Stretch reduces nephrin expression via an angiotensin II-AT(1)-dependent mechanism in human podocytes: effect of rosiglitazone. Am. J. Physiol. Renal Physiol. 298, F381-F390 (2010).
28. Liang, Y. J. et al. L-165,041, troglitazone and their combination treatment to attenuate high glucose-induced receptor for advanced glycation end products (RAGE) expression. Eur. J. Pharmacol. 715, 33-38 (2013).
29. Routh, R. E., Johnson, J. H. & McCarthy, K. J. Troglitazone suppresses the secretion of type I collagen by mesangial cells in vitro. Kidney Int. 61, 1365-1376 (2002).
30. Kang, B.-Y. et al. Hypoxia mediates mutual repression between microRNA-27a and PPARγ in the pulmonary vasculature. PLoS One 8, e79503 (2013).
31. Zafiriou, S. et al. Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts. J. Am. Soc. Nephrol. 16, 638-645 (2005).
32. Nicholas, S. B., Kawano, Y., Wakino, S., Collins, A. R. & Hsueh, W. A. Expression and function of peroxisome proliferator-activated receptor-γ in mesangial cells. Hypertension 37, 722-727 (2001).
33. Krützfeldt, J. et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 438, 685-689 (2005).
34. Esau, C. et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 3, 87-98 (2006).
35. Davis, S. et al. Potent inhibition of microRNA in vivo without degradation. Nucleic Acids Res. 37, 70-77 (2009).
36. Kato, M. et al. MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc. Natl. Acad. Sci. USA 104, 3432-3437 (2007).
37. Long, J., Wang, Y., Wang, W., Chang, B. H. & Danesh, F. R. MicroRNA-29c is a signature microRNA under high glucose conditions that targets sprouty homolog 1, and its in vivo knockdown prevents progression of diabetic nephropathy. J. Biol. Chem. 286, 11837-11848 (2011).
38. Wang, Q. et al. MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy. FASEB J. 22, 4126-4135 (2008).
39. Li, J. H., Huang, X. R., Zhu, H. J., Johnson, R. & Lan, H. Y. Role of TGF-beta signaling in extracellular matrix production under high glucose conditions. Kidney Int. 63, 2010-2019 (2003).